COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 1935: Articles 19341-19350  | Next

Distinct mutations and lineages of SARS-CoV-2 virus in the early phase of COVID-19 global pandemic and subsequent global expansion
Chen, Y., Li, S., Wu, W., Geng, S., Mao, M.
10.1101/2021.01.05.425339 — Posted: 2021-01-06
Self-organized stem cell-derived human lung buds with proximo-distal patterning and novel targets of SARS-CoV-2
Rosado-Olivieri, E. A., Razooky, B., Hoffmann, H.-H., De Santis, R., Rice, C. M., Brivanlou, A. H.
10.1101/2021.01.06.425622 — Posted: 2021-01-06
SARS-CoV-2 spike downregulates tetherin to enhance viral spread
Stewart, H., Johansen, K. H., McGovern, N., Palmulli, R., Carnell, G. W., Heeney, J. L., Okkenhaug, K., Firth, A., Peden, A. A., Edgar, J. R.
10.1101/2021.01.06.425396 — Posted: 2021-01-06 Discussion: Offsite
Natural variants in SARS-CoV-2 S protein pinpoint structural and functional hotspots; implications for prophylaxis strategies
Mochly-Rosen, D., Kraemer, B. R., Pokhrel, S.
10.1101/2021.01.04.425340 — Posted: 2021-01-06
Role of spatial patterning of N-protein interactions in SARS-CoV-2 genome packaging
Seim, I., Roden, C., Gladfelter, A.
10.1101/2021.01.06.425605 — Posted: 2021-01-06
SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor
Zahradnik, J., Marciano, S., Shemesh, M., Zoler, E., Chiaravalli, J., Meyer, B., Dym, O., Elad, N., Schreiber, G.
10.1101/2021.01.06.425392 — Posted: 2021-01-06 Discussion: Onsite
Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19
Kamle, S., Ma, B., He, C. H., Akosman, B., Zhou, Y., Lee, C.-M., El-Deiry, W. S., Huntington, K., Liang, O., Machan, J. T., Kang, M.-J., Shin, H. J., Mizoguchi, E., Lee, C. G., Elias, J. A.
10.1101/2021.01.05.425478 — Posted: 2021-01-06
Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro
Kayabolen, A., Akcan, U., Ozturan, D., Sarayloo, E., Nurtop, E., Ozer, B., Sahin, G. N., Dogan, O., Lack, N., Kaya, M., Albayrak, C., Can, F., Solaroglu, I., Bagci-Onder, T.
10.1101/2021.01.04.425128 — Posted: 2021-01-06
RNA-protein interaction analysis of SARS-CoV-2 5'- and 3'-untranslated regions identifies an antiviral role of lysosome-associated membrane protein-2
Verma, R., Saha, S., Kumar, S., Mani, S., Maiti, T. K., Surjit, M.
10.1101/2021.01.05.425516 — Posted: 2021-01-06
COVID-19 virtual patient cohort reveals immune mechanisms driving disease outcomes
Jenner, A. L., Aogo, R. A., Alfonso, S., Crowe, V., Smith, A. P., Morel, P. A., Davis, C. L., Smith, A. M., Craig, M.
10.1101/2021.01.05.425420 — Posted: 2021-01-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).